LR-20062 is under clinical development by LG Chem and currently in Phase I for Tetanus. According to GlobalData, Phase I drugs for Tetanus have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LR-20062’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LR-20062 overview
LR-20062 is under development for the prevention of pertussis (whooping cough), diphtheria, tetanus, poliomyelitis, Haemophilus influenza type b, hepatitis B infections and meningitis.
LG Chem overview
LG Chem is a chemical manufacturer. The company manufactures and markets products related to petrochemicals, advanced materials, and life science. Its product portfolio includes acrylonitrile butadiene styrene, acrylonitrile styrene acrylate, acrylate, alcohol, bisphenol, butadiene rubber, die attach film, display stripper double-sided tape, OLED materials, battery materials, among others. It also offers life science products related to arthritis, diabetes, growth hormone, circulatory system, fertility, anemia, hyperkalemia, and crop protection agents, among others. LG Chem’s products find applications in automobiles, home appliances, packaging, agriculture, textiles, and industrial products, among others. The company has operations in China, India, Germany, the US, Vietnam, Brazil, Taiwan, Hong Kong and Poland, among others. LG Chem is headquartered in Seoul, South Korea.
For a complete picture of LR-20062’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
